PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.12
D/E ratio 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 0.09. Seth Klarman would look for hidden assets or restructuring potential.
-14.98
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.09. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
14.00
Coverage of 14.00 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
17.39
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.90. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
0.98%
Intangibles less than half the Drug Manufacturers - Specialty & Generic median of 10.16%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.